Suppr超能文献

10年期间铜绿假单胞菌血症:移植受者的多重耐药性及预后

Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients.

作者信息

Johnson L E, D'Agata E M C, Paterson D L, Clarke L, Qureshi Z A, Potoski B A, Peleg A Y

机构信息

Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

出版信息

Transpl Infect Dis. 2009 Jun;11(3):227-34. doi: 10.1111/j.1399-3062.2009.00380.x. Epub 2009 Mar 2.

Abstract

AIM

Transplant recipients are at risk for hospital-acquired infections (HAIs), including those caused by Pseudomonas aeruginosa. Of all HAIs, bloodstream infection (BSI) remains one of the most life-threatening.

METHODS

Over a 10-year period, we studied 503 patients, including 149 transplant recipients, with pseudomonal BSI from the University of Pittsburgh Medical Center. Trends in antimicrobial susceptibility, risk factors for multidrug resistance (MDR), and outcomes were compared between transplant and non-transplant patients.

RESULTS

Resistance to all antibiotic classes was significantly greater in pseudomonal blood culture isolates from transplant compared with non-transplant patients (P<0.001). Of isolates from transplant recipients (n=207), 43% were MDR, compared with 18% of isolates from non-transplant patients (n=391) (odds ratio [OR] 3.47; 95% confidence interval [CI] 2.34-5.14, P<0.001). Among all patients, independent risk factors for MDR P. aeruginosa BSI included previous transplantation (OR 2.38; 95% CI 1.51-3.76, P<0.001), hospital-acquired BSI (OR 2.41; 95% CI 1.39-4.18, P=0.002), and prior intensive care unit (ICU) admission (OR 2.04; 95% CI 1.15-3.63, P=0.015). Mortality among transplant recipients was 42%, compared with 32% in non-transplant patients (OR 1.55; 95% CI 0.87-2.76, P=0.108). For transplant recipients, onset of BSI in the ICU was the only independent predictor of mortality (OR 8.00; 95% CI 1.71-37.42, P=0.008).

CONCLUSIONS

Transplant recipients are at greater risk of MDR P. aeruginosa BSI, with an appreciable mortality. Future management must concentrate on the implementation of effective preventative strategies.

摘要

目的

移植受者有发生医院获得性感染(HAIs)的风险,包括由铜绿假单胞菌引起的感染。在所有医院获得性感染中,血流感染(BSI)仍然是最危及生命的感染之一。

方法

在10年期间,我们研究了来自匹兹堡大学医学中心的503例患者,包括149例有铜绿假单胞菌血流感染的移植受者。比较了移植患者和非移植患者在抗菌药物敏感性、多重耐药(MDR)危险因素及转归方面的趋势。

结果

与非移植患者相比,移植患者的铜绿假单胞菌血培养分离株对所有抗生素类别的耐药性均显著更高(P<0.001)。在移植受者的分离株(n=207)中,43%为多重耐药,而非移植患者的分离株(n=391)中这一比例为18%(比值比[OR]3.47;95%置信区间[CI]2.34-5.14,P<0.001)。在所有患者中,多重耐药铜绿假单胞菌血流感染的独立危险因素包括既往移植(OR 2.38;95%CI 1.51-3.76,P<0.001)、医院获得性血流感染(OR 2.41;95%CI 1.39-4.18,P=0.002)以及既往入住重症监护病房(ICU)(OR 2.04;95%CI 1.15-3.63,P=0.015)。移植受者的死亡率为42%,而非移植患者为32%(OR 1.55;95%CI 0.87-2.76,P=0.108)。对于移植受者,在ICU发生血流感染是唯一独立的死亡预测因素(OR 8.00;95%CI 1.71-37.42,P=0.008)。

结论

移植受者发生多重耐药铜绿假单胞菌血流感染的风险更高,且死亡率可观。未来的管理必须集中于实施有效的预防策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验